Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial

BMJ. 2009 Dec 16:339:b4984. doi: 10.1136/bmj.b4984.

Abstract

Objective: To determine the clinical effectiveness of topical intranasal corticosteroids in children with bilateral otitis media with effusion.

Design: Double blind randomised placebo controlled trial.

Setting: 76 Medical Research Council General Practice Research Framework practices throughout the United Kingdom, between 2004 and 2007.

Participants: 217 children aged 4-11 years who had at least one practice recorded episode of otitis media or a related ear problem in the previous 12 months, and with bilateral otitis media with effusion confirmed by a research nurse using otoscopy plus micro-tympanometry (B/B or B/C2, modified Jerger types).

Intervention: Mometasone furoate 50 microg or placebo spray given once daily into each nostril for three months.

Main outcome measures: Proportions of children cured of bilateral otitis media with effusion assessed with tympanometry (C1 or A type) at one month (primary end point), three months, and nine months; adverse events; three month diary symptoms. Results 41% (39/96) of the topical steroid group and 45% (44/98) of the placebo group were cured in one or both ears at one month (difference favouring placebo 4.3% (95% confidence interval -9.3% to 18.1%). Poisson regression was done with adjustment for four pre-specified covariates (clinical severity, P=0.003; atopy, P=0.67; age, P=0.92; season, P=0.71). The adjusted relative risk at one month was 0.97 (95% confidence interval 0.74 to 1.26). At three months, 58% of the topical steroid group and 52% of the placebo group were cured (relative risk 1.23, 0.84 to 1.80). Diary symptoms did not differ between the two groups, and no significant harms were reported.

Conclusions: Topical steroids are unlikely to be an effective treatment for otitis media with effusion in general practice. High rates of natural resolution occurred by 1-3 months.

Trial registration: Current Controlled Trials ISRCTN38988331; National Research Register NO575123823; MREC 03/11/073.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intranasal
  • Anti-Inflammatory Agents / administration & dosage*
  • Child
  • Child, Preschool
  • Chronic Disease
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Mometasone Furoate
  • Otitis Media with Effusion / drug therapy*
  • Pregnadienediols / administration & dosage*
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Pregnadienediols
  • Mometasone Furoate

Associated data

  • ISRCTN/ISRCTN38988331